Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16520915 | 1.00 | SIGMAR1 (0.68) | SIGMAR1CYP1A2EPHX1MEN1KMT2A | |
| SCHEMBL22838527 | 1.00 | SIGMAR1 (0.68) | SIGMAR1CYP1A2EPHX1MEN1KMT2A | |
| SCHEMBL22341229 | 1.00 | SIGMAR1 (0.68) | SIGMAR1CYP1A2EPHX1MEN1KMT2A | |
| SCHEMBL629800 | 1.00 | SIGMAR1 (0.68) | SIGMAR1CYP1A2EPHX1MEN1KMT2A | |
| SCHEMBL22520986 | 1.00 | SIGMAR1 (0.68) | SIGMAR1CYP1A2EPHX1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2192001 | 0.97 | SIGMAR1 (0.65) | SIGMAR1CYP1A2EPHX1MEN1KMT2A | |
| SCHEMBL1680312 | 0.97 | — | — | |
| SCHEMBL919693 | 0.92 | — | — | |
| Methylamine SCHEMBL28480964 | 0.90 | SIGMAR1 (0.57) | SIGMAR1CYP1A2EPHX1MEN1KMT2A | |
| SCHEMBL17919936 | 0.86 | SIGMAR1 (0.50) | SIGMAR1CYP1A2EPHX1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2941423-B1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | UNIV SOUTHERN CALIFORNIA (US) | 2021-06-09 | — | — | EP | disclosed |
| US-10391095-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-27 | — | — | US | disclosed |
| US-9878993-B2 | DNA-PK inhibitors for treatment of cancer | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170258789-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258789-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | SIGMAR1 4343/4885CYP1A2 2215/4885EPHX1 3247/4885 |
| US-10391095-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | SIGMAR1 4343/4885CYP1A2 2215/4885EPHX1 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.